Investigators examined 6 biomarkers for predicting adverse cardiovascular outcomes in patients with type 2 diabetes.
All articles by Endocrinology Advisor Contributing Writer
Liraglutide may reduce the incidence of myocardial infarction in patients who have a high cardiovascular risk with type 2 diabetes.
Publish Date
-
Latest News Your top articles for Saturday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses